Jack Diteodoro, MD
Family Medicine · Stamford, CTNPI 1346338837
Payments from drug & device makers
Across 58 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$238
- AbbVie$182
- Ardelyx, Inc.$111
- Boehringer Ingelheim$98
- Novo Nordisk$86
- Merck$66
- plus $356 from 12 others
What the payments were for
- Food & beverage$1,136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $238 |
| AbbVie(2 entities) | 6 | $182 |
| Ardelyx, Inc. | 5 | $111 |
| Boehringer Ingelheim | 5 | $98 |
| Novo Nordisk | 5 | $86 |
| Merck | 4 | $66 |
| Exact Sciences | 2 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Scilex Pharmaceuticals Inc. | 1 | $45 |
| Pfizer | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Urovant Sciences Inc | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Novartis | 1 | $16 |
| GSK | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,136 in reported general payments places this provider in the 70th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,619 | $348,323 |
| AustedoDeutetrabenazine | 104 | $266,679 |
| JanuviaSitagliptin Phosphate | 349 | $101,113 |
| TrulicityDulaglutide | 83 | $88,146 |
| FarxigaDapagliflozin Propanediol | 344 | $85,785 |
| OzempicSemaglutide | 69 | $85,668 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $58,889 |
| XareltoRivaroxaban | 259 | $49,832 |
| XifaxanRifaximin | 34 | $48,626 |
| MyrbetriqMirabegron | 223 | $36,863 |
| JardianceEmpagliflozin | 186 | $35,129 |
| Xtampza ErOxycodone Myristate | 13 | $30,705 |
| SantylCollagenase Clostridium Hist. | 60 | $29,344 |
| LinzessLinaclotide | 50 | $28,537 |
| IsentressRaltegravir Potassium | 11 | $23,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $348,3231,619 claims |
| MerckJanuvia, Isentress, Janumet | $66 | $135,465436 claims |
| AstraZenecaFarxiga | $238 | $85,785344 claims |
| Novo NordiskOzempic | $86 | $85,66869 claims |
| Boehringer IngelheimJardiance, Tradjenta | $98 | $46,170216 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $36,863223 claims |
| AbbVieLinzess | $182 | $28,53750 claims |
| NovartisEntresto | $16 | $22,798123 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $14 | $15,89639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Stamford
- Debra GramlichStamford$292K
- Nicole NelsonStamford$19K
- Natasha FergusonStamford$7K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.